Clinical Trials Logo

Clinical Trial Summary

Even at the disease onset, about 70% of patients with multiple sclerosis (MS) suffer from cognitive impairment that impacts quality of life. Currently, some speed processing tests are used, such as SDMT ( symbol digit modalities test ), CSCT (information treatment speed evaluation) and WAIS-IV (Weschler Adult Intelligence Scale ). Their inconvenient are the improvement of scores in test-retest, and some difficulties doing the tests due to motor or visual impairment that might be reported. The XO test is fast, cheap and easy to use during medical consult by neurologists. It seems to be correlated to results of speed processing tests, and probably to some executive functions tests too. Asthenia, anxiety, depression and pain are likely to have a negative influence on tests results. Screening every patients with a short test aims to detect patients with cognitive impairment earlier. After a positive screening test, and to better characterize cognitive impairment, they will undergo a neuropsychological test battery. Depending on the alteration, adapted workstation, financial support, technical and human helps will be implemented in order to improve the daily-living of patients.

This study aims to approve the XO as a screening test of cognitive impairment in MS patients. We will study the relationship between XO test, and SDMT, CSCT, WAIS-IV, and also with questionnaires about pain, asthenia (FSS, Fatigue Severity Scale), anxiety and depression (HAD, Hospital Anxiety and Depression ). The XO test will be standardized using a healthy population.


Clinical Trial Description

Even at the disease onset, about 70% of patients with multiple sclerosis (MS) suffer from cognitive impairment that impacts quality of life. Currently, some speed processing tests are used, such as SDMT, CSCT and WAIS-IV. Their inconvenient are the improvement of scores in test-retest, and some difficulties doing the tests due to motor or visual impairment that might be reported. The XO test is fast, cheap and easy to use during medical consult by neurologists. It seems to be correlated to results of speed processing tests, and probably to some executive functions tests too. Asthenia, anxiety, depression and pain are likely to have a negative influence on tests results. Screening every patients with a short test aims to detect patients with cognitive impairment earlier. After a positive screening test, and to better characterize cognitive impairment, they will undergo a neuropsychological test battery. Depending on the alteration, adapted workstation, financial support, technical and human helps will be implemented in order to improve the daily-living of patients.

This study aims to approve the XO as a screening test of cognitive impairment in MS patients. We will study the relationship between XO test, and SDMT, CSCT, WAIS-IV, and also with questionnaires about pain, asthenia (FSS), anxiety and depression (HAD). The XO test will be standardized using a healthy population. 140 multiple sclerosis patients (90 relapsing remitting, and 50 progressive) and 400 healthy controls must be recruited.

Multiple sclerosis patients included must :

- Be men or women aged 18 or more

- Be diagnosed with Multiple Sclerosis (MacDonald criteria, 2017)

- Absence of relapse in the previous month

- Be mother-tongue French, or speaking French fluently

- Be covered by French social security

Healthy controls included must :

- Be men or women aged 18 or more

- Suffer from no pathology that might be incompatible with the study

People who can't be included :

- Patients or controls declining participation to the study, or legally protected, pregnant or breastfeeding women

- Patients suffering from another neurological disease, psychiatric disorder, or developmental abnormalities that were diagnosed before multiple sclerosis

- Patients with cranial trauma, relapse that ended less than 1 month before, or depression in the last 3 months

- Patients with severe motor or visual disabilities There are 4 centers. This is a prospective cohort study, in which data will be collected during a single appointment.

The score obtained doing XO test is the dependent variable that will be compared to the variables due to speed processing and executive functions tests. Test-retest of XO test will also be assessed. The percentage of wrong answers doing XO test will be investigated.

The study is going to last 18 months. Every patient (140) and healthy control (400) will fill in all the tests and questionnaires, except FSS (fatigue severity scale), in a random order during a single appointment. The FSS will be filled in by patients only. All 400 healthy controls will be divided in 20 groups of 20 people, due to gender, age (5 classes: 18-33, 34-43, 44-54, 55-64, and more than 65 years old), and level of education (graduated or not). 60 of them will undergo the XO test at the beginning and again at the end of the appointment to investigate the test-retest effect. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03999034
Study type Interventional
Source University Hospital, Clermont-Ferrand
Contact Lise LACLAUTRE
Phone +334.75.754.963
Email drci@chu-clermontferrand.fr
Status Recruiting
Phase N/A
Start date July 8, 2019
Completion date October 8, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05273125 - MOBility Disorders Assessment in Patients With Mild COGnitive Disorders
Active, not recruiting NCT04049695 - Improving Cognition After Cancer N/A
Completed NCT05912374 - Adapting a Behavioral Intervention to Accommodate Cognitive Dysfunction in People Who Inject Drugs N/A
Recruiting NCT03977350 - Association Between qEEG Measure and Post-Operative Cognitive Dysfunction (POCD) and Postoperative Delirium (POD)
Not yet recruiting NCT06027632 - Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer N/A
Completed NCT00719628 - Depth of Anaesthesia and Cognitive Dysfunction N/A
Terminated NCT00754052 - Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17 Phase 3
Terminated NCT00754013 - Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10 Phase 3
Recruiting NCT05014399 - Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
Completed NCT04966455 - Effect of Raisins on Cognitive Function in Healthy Older Adults Phase 3
Recruiting NCT05372159 - Vanderbilt Memory and Aging Project
Completed NCT03243279 - BRS and Outcomes in Cardiothoracic Surgery
Completed NCT04093882 - The Relevance of the Blood-brain Barrier to Cognitive Dysfunction and Alzheimer's Disease
Recruiting NCT05732285 - A Pilot Randomized Controlled Trial: CoINTEGRATE N/A
Completed NCT06059768 - Urdu Translation and Psychometric Analysis of Lawton IADLS.
Completed NCT04562662 - Evaluation of mediVR-KAGURA Guided Therapy N/A
Completed NCT04624529 - Validity and Reliability of a Self-evaluation Tool for Cognitive Deficits in the Acute Stage After Stroke
Not yet recruiting NCT04079075 - Multiple Interventions to Prevent Cognitive Decline N/A
Active, not recruiting NCT04638101 - Building the Path to Resilience in Preterm Infants: Mindfulness-based Intervention N/A
Active, not recruiting NCT04556305 - Lifestyle Physical Activity and Cognitive Training Interventions N/A